Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Prima BioMed to Host Investor Days in Australia


Print article Print article
© Marketwire 2013
2013-01-24 02:17:54 -

SYDNEY, AUSTRALIA -- (Marketwire) -- 01/23/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") is pleased to announce upcoming investor days at several major Australian cities in February.



Prima CEO, Matthew Lehman will host the sessions, to be held in Sydney, Melbourne, Brisbane and Perth, in the week commencing 4 February 2013.





Mr. Lehman will provide an update on the Company's business and attendees will have an opportunity for Q&A.



Details of dates and venues are provided below.



Perth
Monday, 4
th February
Parmelia Hilton Hotel, 14 Mill St, Perth
10.00am - 11.30am local time



Melbourne
Tuesday, 5
th February
Westin Melbourne Hotel, 205 Collins St, Melbourne
10.30am - 12.00noon local time



Brisbane
Wednesday, 6
th February
Hilton Brisbane Hotel, 190 Elizabeth St, Brisbane
10.00am - 11.30am local time



Sydney
Thursday, 7
th February
Radisson Blu Hotel, 27 O'Connell St, Sydney
10.30am - 12.00noon local time



Shareholders and other interested parties are kindly requested to help assure appropriate accommodations by sending an RSVP by email to enquiries@primabiomed.com.au : mailto:enquiries@primabiomed.com.au and identify the city of attendance by Friday 1st February.



About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.




For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Email Contact : www2.marketwire.com/mw/emailprcntct?id=0F3A7892D4BB012C

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact : www2.marketwire.com/mw/emailprcntct?id=2D66533B7FCE041A

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact : www2.marketwire.com/mw/emailprcntct?id=49AB111095861319



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com